New Strategies for Medical Management of Castration-Resistant Prostate Cancer
| Autor: | Jean-Emmanuel Kurtz, Philippe Barthélémy, Patrick Dufour, Irène Asmane, Valère Litique, Jocelyn Céraline, Lynn Rob, Brigitte Duclos, Jean-Pierre Bergerat |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Neoplasms Hormone-Dependent medicine.medical_treatment Salvage therapy Antineoplastic Agents Docetaxel urologic and male genital diseases Targeted therapy Prostate cancer Internal medicine Humans Medicine Molecular Targeted Therapy business.industry Prostatic Neoplasms Steroid 17-alpha-Hydroxylase Cancer General Medicine medicine.disease Surgery Clinical trial Receptors Androgen Hormonal therapy Taxoids Hormone therapy business Orchiectomy medicine.drug |
| Zdroj: | Oncology. 80:1-11 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000323495 |
| Popis: | Although advanced prostate cancer patients respond very well to front-line androgen deprivation, failure to hormonal therapy most often occurs after a median time of 18–24 months. The care of castration-resistant prostate cancer (CRPC) has significantly evolved over the past decade, with the onset of first-line therapy with docetaxel. Although numerous therapy schedules have been investigated alongside docetaxel, in either first-line or salvage therapy, results were dismal. However, CRPC chemotherapy is currently evolving, with, on the one hand, new agents targeting androgen metabolism and, on the other hand, significant progress in chemotherapy drugs, particularly for second-line therapy. The aim of the present review is to describe the current treatments for CRPC chemotherapy alongside their challengers that might shortly become new standards. In this article, we discuss the most recent data from clinical trials to provide the reader with a comprehensive, state-of-the-art overview of CRPC chemotherapy and hormonal therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|